Catalyst Biosciences, Inc. has received a $4.0 million milestone payment from Pfizer under their collaboration agreement for the development of recombinant human Factor VIIa variants for the treatment of hemophilia and other bleeding disorders. “We are very encouraged by the progress made to date in our Factor VIIa program, the most advanced program within Catalyst’s hemostasis franchise,” said Nassim Usman, Ph.D., Catalyst’s chief executive officer.”In addition ...